Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), filed a Form 4 on November 3, 2026, disclosing option exercises and open-market sales of Class A Ordinary Shares on October 30, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Four option tranches exercised: Megna exercised options covering 4,689 shares at $10.76, 3,932 shares at $11.10, 7,209 shares at $11.97, and 4,065 shares at $17.76, all on October 30, 2026.
  • Seven sale tranches executed: A combined 36,260 Class A Ordinary Shares were sold on October 30, 2026, at weighted average prices ranging from $91.87 to $97.74 per share, with individual trade prices spanning $91.275 to $98.48.
  • Remaining beneficial ownership: Following all reported transactions, Megna directly held 12,697 Class A Ordinary Shares, according to the filing.
  • 10b5-1 plan: All transactions were effected pursuant to a plan executed by Megna on July 30, 2026, the filing states.
  • Remaining derivative securities: After the exercises, Megna retained 0 options at the $11.10 and $11.97 exercise prices, 2,983 options at $10.76, and 16,394 options at $17.76, all directly held.

Megna's October 30, 2026 Option Exercises and Share Sales at Kiniksa Pharmaceuticals

According to the filing, Michael R. Megna, serving as Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, carried out a series of transactions on October 30, 2026. He exercised four share option tranches using transaction code "M," acquiring a total of 19,895 Class A Ordinary Shares at exercise prices of $10.76, $11.10, $11.97, and $17.76. The filing notes two of those option series were fully vested and exercisable at the time of exercise.

On the same date, Megna disposed of shares across seven separate sale tranches, identified by transaction code "S." The filing reports weighted average sale prices of $91.87, $92.77, $94.20, $94.86, $96.08, $97.11, and $97.74 per share for the respective tranches. Each sale was executed through a broker-dealer in multiple trades, and the filing notes that full information on the number of shares sold at each individual price is available upon request to SEC staff. After all disposals, Megna's directly held position in Class A Ordinary Shares stood at 12,697, as reported in the filing.

The filing confirms all transactions were made pursuant to a Rule 10b5-1(c) plan that Megna adopted on July 30, 2026. The form was signed by Douglas Barry as Attorney-in-Fact and filed on November 3, 2026. Remaining unexercised options include 2,983 options at a $10.76 exercise price expiring March 31, 2033, and 16,394 options at a $17.76 exercise price expiring August 31, 2033, both subject to ongoing vesting schedules described in the filing.

What Was Disclosed

Kiniksa Pharmaceuticals International's Chief Accounting Officer, Michael R. Megna, disclosed the exercise of four stock option tranches totaling 19,895 shares and the sale of 36,260 Class A Ordinary Shares on October 30, 2026, all under a pre-established 10b5-1 trading plan.